The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials
American Journal of Psychiatry · 01.03.2025 · 182 (3) · 297-306
DOI: 10.1176/appi.ajp.20240076 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Psychiatry, erschienen am 01.03.2025. Verfasst von William P Horan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Boston (Horan, Sauder, Ramsay, Yohn, Paul, Brannan); University of Miami Miller School of Medicine, Miami (Harvey); Duke Univer…. Hauptthemen laut MEDLINE: Benzilates, Cognitive Dysfunction, Nortropanes, Schizophrenia. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Xanomeline and trospium chloride (formerly known as KarXT), a novel M1/M4 muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as monotherapy for the treatment of inpatients with acute schizophrenia on the Positive and Negative Syndrome Scale total score primary endpoint. In the phase 2 trial, xanomeline/trospium improved performance on a cognitive outcome measure in the subgroup of participants with clinically significant baseline cognitive impairment. The authors sought to confirm this finding using data from two phase 3 trials. METHODS: Data were pooled from two 5-week inpatient trials of xanomeline/trospium monotherapy in patients with acute schizophrenia. The statistical analysis plan prespecified comparisons of cognitive composite score changes between xanomeline/trospium and placebo in the full sample and the cognitively impaired (≤1 SD below norms at baseline) subgroup. RESULTS: There was no significant xanomeline/trospium effect in the full sample (N=357); however, in the impaired subgroup, xanomeline/trospium (N=71) had a significantly greater benefit for cognition compared with placebo (N=66; least squares mean difference=0.31, SE=0.10; d=0.54). The xanomeline/trospium effect size increased significantly with a more stringent baseline impairment threshold (≤-1.5 SD; d=0.80). Improvements in cognition were minimally correlated with concurrent changes in total, positive, and negative symptoms in both treatment groups. CONCLUSIONS: Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. This result directly confirms earlier findings. This benefit is not attributable to changes in symptoms, despite substantial evidence of efficacy for psychosis. Evaluation of xanomeline/trospium's potential for cognitive enhancement in a well-controlled trial of stable patients with cognitive impairment is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb, Boston (Horan, Sauder, Ramsay, Yohn, Paul, Brannan); University of Miami Miller School of Medicine, Miami (Harvey); Duke University School of Medicine, Durham (Keefe); Statistical Consultant, Chape…
Zitieren
APA
Horan, W. P., Sauder, C., Harvey, P. D., Ramsay, I. S., Yohn, S. E., Keefe, R. S. E., Davis, V. G., Paul, S. M., & Brannan, S. K. (2025). The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. American Journal of Psychiatry, 182(3), 297-306. https://doi.org/10.1176/appi.ajp.20240076
Vancouver
Horan WP, Sauder C, Harvey PD, Ramsay IS, Yohn SE, Keefe RSE, et al. The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. American Journal of Psychiatry. 2025;182(3):297-306. doi:10.1176/appi.ajp.20240076
BibTeX
@article{Horan2025,
author = {Horan, William P and Sauder, Colin and Harvey, Philip D and Ramsay, Ian S and Yohn, Samantha E and Keefe, Richard S E and Davis, Vicki G and Paul, Steven M and Brannan, Stephen K},
title = {The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials},
journal = {American Journal of Psychiatry},
year = {2025},
volume = {182},
number = {3},
pages = {297--306},
doi = {10.1176/appi.ajp.20240076}
}
EUVIMED